Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) and Vivani Medical (NASDAQ:VANI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
Volatility & Risk
Aclaris Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Vivani Medical has a beta of 3.07, meaning that its stock price is 207% more volatile than the S&P 500.
Institutional and Insider Ownership
98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 5.6% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 46.4% of Vivani Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Aclaris Therapeutics | -900.01% | -39.73% | -27.98% |
| Vivani Medical | N/A | -293.64% | -79.49% |
Earnings and Valuation
This table compares Aclaris Therapeutics and Vivani Medical”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aclaris Therapeutics | $15.74 million | 30.97 | -$132.07 million | ($1.38) | -3.26 |
| Vivani Medical | N/A | N/A | -$23.49 million | ($0.45) | -3.29 |
Vivani Medical has lower revenue, but higher earnings than Aclaris Therapeutics. Vivani Medical is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and price targets for Aclaris Therapeutics and Vivani Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aclaris Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
| Vivani Medical | 1 | 1 | 1 | 0 | 2.00 |
Aclaris Therapeutics presently has a consensus target price of $9.75, indicating a potential upside of 116.67%. Vivani Medical has a consensus target price of $4.00, indicating a potential upside of 170.27%. Given Vivani Medical’s higher probable upside, analysts plainly believe Vivani Medical is more favorable than Aclaris Therapeutics.
Summary
Aclaris Therapeutics beats Vivani Medical on 7 of the 13 factors compared between the two stocks.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
About Vivani Medical
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
